The Centers for Medicare & Medicaid Services (CMS) have unveiled preliminary 2027 payment rates for clinical lab services. This move could alter how millions on Medicare receive reimbursements for laboratory tests. The new rates rely on private insurer payment data as per the Protecting Access to Medicare Act (PAMA). The law aims to align Medicare payments with market prices.
CMS indicates that Medicare is currently paying approximately 16% more for laboratory services than private insurers. With the projected changes, CMS estimates taxpayer savings of about $1 billion annually. Dr. Mehmet Oz, CMS Administrator, highlighted the agency’s focus on transparency and reducing excessive rates. He emphasized balancing payments with those of private insurers.
Impact of Laboratory Testing Costs
Lab testing is essential in healthcare, contributing to everything from routine check-ups to advanced diagnostics. While the new rates don’t directly alter out-of-pocket expenses for Medicare beneficiaries, they affect lab revenues. This change is part of a larger debate about whether Medicare’s payment methods truly reflect lab service costs. CMS believes the new rates will reflect the market accurately and reduce excessive spending. But some lab groups warn that reimbursement cuts could limit patient access, especially in rural or less-served areas.
Details of Payment Changes
According to CMS’s preliminary data, there are sector-specific changes in reimbursements. Potential reductions in genomic sequencing payments stand at 23%, molecular pathology at 22%, microbiology at 19.3%, and immunology tests at 19.3%. Chemistry tests, including routine blood work, may see a 16% reduction on average.
Certain proprietary laboratory analysis tests have a smaller decrease of about 2.4%. Since PAMA’s enactment in 2014, this is the second full cycle of data reporting for many lab tests. Congress postponed the process until 2026, allowing updated data to influence 2027 rates. These reductions, capped at 15% annually through 2029, will be gradual.
Kevin Thompson, the CEO of 9i Capital Group, supports using private insurance data for more consistent industry pricing. He acknowledges additional Medicare costs not seen in simple service valuations. CMS will accept public comments on these preliminary rates for 30 days before finalizing them later in the year.
Industry Reaction
Quest Diagnostics criticized the preliminary rates. They argue that the PAMA reporting system has flaws and call for Congress to reform it with the RESULTS Act. Quest advocates for a broader reporting framework and improved data collection. Over 130 Congressional members and 70 organizations, such as the American Medical Association, back this legislative change.
Quest’s survey indicates that 96% of voters see lab testing as vital for healthcare, and 74% urge Congress to prevent further cuts. Kevin Thompson points out the balancing act between costs covered by Medicare compared to private insurers with more restrictions and denials.
The American Clinical Laboratory Association states that almost 1,200 lab tests could face reductions. This includes numerous tests at a 15% cut in 2027. Alex Beene from the University of Tennessee at Martin notes the potential economic impact on smaller labs.
Next Steps
The public can comment on the proposed rates for 30 days. CMS will review all input before finalizing the 2027 Clinical Laboratory Fee Schedule in November. Looking ahead, there is concern about Medicare possibly resembling Medicare Advantage more closely, with increased prior authorizations. Thompson warns of possible trade-offs as reimbursement rates decline. These could ripple across the healthcare system, affecting service access and costs.